Bayer : Not intended for U.S. and UK Media -- Two abstracts on Phase III COMPASS study with Bayer’s Rivaroxaban accepted for presentation in Hot Line sessions at ESC Congress 2017 -- Results from COMPASS, the largest clinical study of rivaroxaban to date, will provide new insights into the management of patients with chronic coronary and peripheral artery disease / COMPASS study was stopped early because of overwhelming efficacy / A total of 17 rivaroxaban abstracts accepted for presentation covering

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go towww.bayer.com.

Follow us on Facebook:http://www.facebook.com/pharma.bayer
Follow us on Twitter:https://twitter.com/BayerPharma

Find more information atwww.bayerpharma.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website atwww.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.